The effect of cholecalciferol supplementation on angiogenic factors in breast cancer survivors co-administered with tamoxife
Phase 2
- Conditions
- Breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT2015082111335N6
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
The range of body mass index (BMI) is 20 to 35 kg/m2
30 – 65 years old
histopathologic confirmed breast malignancy
histopathologic grades of 2 and 3
tendency to participate in study
completed questionnaire
tamoxifen consumption
Exclusion Criteria
Being at clinical stage 4
pregnancy
lactation
acute renal or liver failure
using antiepileptic medications and contraceptive drugs
history of hormonal related diseases (such as diabetes, hyperthyroidism and poly cystic ovary syndrome)
nausea
vomiting
headache
vertigo
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum levels of angiopoietin-2 and VEGF-A. Timepoint: Baseline and 8 week after baseline. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method Anthropometric parameters. Timepoint: Baseline and 8 week after baseline. Method of measurement: Waist circumference, body mass index (kg/m2), and waist to hip ratio.